Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Alumis Inc.

Market Cap 3.14B 2.74B 2.53B 2.37B 4.44B 296B 4.47B 30.12B 11.72B 146B 11.78B 11.52B 506B P/E 2026 *
-8.56x
P/E 2027 * -9x
Enterprise Value 2.6B 2.27B 2.1B 1.96B 3.68B 246B 3.71B 24.99B 9.72B 121B 9.77B 9.56B 420B EV / Sales 2026 *
333x
EV / Sales 2027 * 116x
Free-Float
96.2%
Yield 2026 *
-
Yield 2027 * -
1 day+5.08%
1 week+6.96%
Current month+13.89%
1 month+11.72%
3 months-1.84%
6 months+120.04%
Current year+152.05%
1 week 22.18
Extreme 22.185
24.9
1 month 18.36
Extreme 18.36
24.9
Current year 7.85
Extreme 7.85
30.6
1 year 2.76
Extreme 2.7601
30.6
3 years 2.76
Extreme 2.7601
30.6
5 years 2.76
Extreme 2.7601
30.6
10 years 2.76
Extreme 2.7601
30.6
Manager TitleAgeSince
Chief Executive Officer 61 2021-09-22
Director of Finance/CFO 61 2022-04-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 62 2021-04-30
Director/Board Member 60 2021-05-31
Chairman 61 2021-09-22
Date Insider Type Main position Quantity % Market Cap.
05-21Fiscal year

Chief Technology Officer

53,704 0.0468%
03-31
Foresite Capital Management LLC
OthersCompany 4,103,630 3.5738%
03-31
Foresite Capital Management LLC
OthersCompany 4,103,630 3.5738%
Change 5-day change 1-year change 3-year change Capi.($)
+5.08%+6.96%+760.14% - 3.14B
+2.87%+4.57%+68.97%+119.22% 56.65B
+4.00%+7.51%+63.67%+68.77% 47.49B
-0.77%-0.67%-15.34%-15.95% 22.81B
+2.93%+1.17%-3.97%+384.78% 21.37B
+0.78%+3.26%+26.53%-17.88% 16.12B
+1.16%+3.86%+20.23%-36.42% 15.56B
-1.08%-3.11%+27.20%+158.30% 12.91B
+3.30%+15.02%+133.24%+273.89% 12.86B
+0.56%-7.24%+20.45% - 11.67B
Average +1.89%+2.64%+110.11%+116.84% 22.06B
Weighted average by Cap. +2.18%+3.32%+54.07%+109.78%

Financials

2026 *2027 *
Net sales 7.82M 6.83M 6.32M 5.9M 11.07M 739M 11.15M 75.07M 29.21M 363M 29.34M 28.71M 1.26B 23.83M 20.83M 19.26M 17.98M 33.76M 2.25B 34M 229M 89.07M 1.11B 89.49M 87.55M 3.85B
Net income -375M -328M -303M -283M -531M -35.42B -535M -3.6B -1.4B -17.42B -1.41B -1.38B -60.5B -397M -347M -321M -299M -562M -37.5B -566M -3.81B -1.48B -18.44B -1.49B -1.46B -64.04B
Net Debt -534M -467M -432M -403M -757M -50.51B -762M -5.13B -2B -24.83B -2.01B -1.96B -86.26B -371M -324M -300M -280M -525M -35.04B -529M -3.56B -1.39B -17.23B -1.39B -1.36B -59.84B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
226
Date Price Change Volume
26-06-22 24.60 $ +5.08% 1,435,836
26-06-18 23.41 $ +1.56% 1,883,737
26-06-17 23.05 $ +3.27% 1,423,531
26-06-16 22.32 $ -2.96% 888,818
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
24.60USD
Average target price
40.10USD
Spread / Average Target
+63.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!